[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498953":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":24,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":24,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Hackensack Meridian Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"15mg IV Ketorolac","ACTIVE_COMPARATOR","Patients will be randomized to 15mg IV ketorolac",[13],"Drug: Ketorolac",{"label":15,"type":10,"description":16,"interventionNames":17},"30mg IV Ketorolac","Patients will be randomized to 30mg IV ketorolac",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Ketorolac","IV Ketorolac for pain",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Biren Bhatt, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","551-996-2000","5485","biren.bhatt@hmhn.org",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Hackensack Univarsity medical Center","RECRUITING","Hackensack","New Jersey","07601","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-74.04347,40.88593,{"lat":48,"lon":47},[51],{"name":52,"role":53,"phone":24,"phoneExt":24,"email":24},"Sujatha Iyengar, PhD","SUB_INVESTIGATOR",{"type":55,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100498953","phase-4-evaluation-of-the-effects-of-ketorolac-dose-on-duration-of-analgesia-in-emergency-department-ed-renal-colic-patients-100498953",false,"NCT05776953","Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients","Evaluation of the Effects of Ketorolac 15mg IV Versus 30mg IV on Duration of Analgesia in Patients Who Present to the Emergency Department With Renal Colic","Inclusion Criteria:\n\nPatients will be included if they present to the Emergency Department with (all of the following):\n\n* Adult emergency department patients \\\u003C 65 years old\n* One or more of the following common ED chief complaints associated with the suspected diagnosis of renal colic. These chief complaints include but are not limited to: flank pain, back pain, abdominal pain, left and\u002For right lower quadrant pain, and\u002For pelvic pain\n* Pain score of 4 or greater on the 0-10 NRS\n* Determination of treatment with IV ketorolac\n\nExclusion Criteria:\n\nPatients will be excluded if any of the following apply:\n\n* Allergy to ketorolac\n* Pregnant patients\n* Previously received analgesic medications within 4 hours prior to administration of ketorolac in our ED\n* Known or stated history of renal insufficiency\n* Body weight \\\u003C 50 kg\n* Age greater than 65 years\n* Patients that do no read\u002Fwrite Spanish or English","ALL","18 Years","65 Years",{"count":67,"type":68},86,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","This is a prospective interventional study examining the effect of ketorolac at doses of 15mg versus 30 mg for duration of analgesia in emergency department patients with suspected renal colic.",[74,75,76,77],"Renal Colic","Flank Pain","Emergencies","Analgesia","2026-05-20",{"date":80,"type":81},"2026-05-22","ACTUAL",{"date":83,"type":81},"2023-12-21",{"date":85,"type":68},"2026-09-01",{"name":5,"class":6},1]